IDEAYA Biosciences (IDYA) Could Be 38% Undervalued On Its Pipeline Narrative
IDEAYA Biosciences (IDYA) has drawn fresh attention after recent share performance moved out of step with its longer term record, prompting investors to reassess what the current US$32.85 price reflects.
Short term momentum has cooled for IDEAYA Biosciences, with the share price falling 2.95% over the last day and 12.93% over the past month, even as the 1 year total shareholder return of 12.27% and 5 year total shareholder return of 43.32% point to a much stronger longer term story.
Scan how IDEAYA Biosciences compares to other oncology and biotech opportunities by reviewing the hand picked 20 high quality undiscovered gems that share strong fundamentals and under the radar potential.
Bulls see the recent pullback as noise against IDEAYA Biosciences’ multi asset pipeline, while bears focus on ongoing losses and execution risk. As you weigh the US$32.85 price tag, the question becomes which side the current valuation leans toward.
Most Popular Narrative: 38% Undervalued
IDEAYA Biosciences is trading at $32.85 against a widely followed fair value estimate of $52.75, so the valuation debate really turns on whether its oncology pipeline can support that gap.
The main factor that needs to go right is successful execution on multiple registrational programs, including darovasertib in uveal melanoma and IDE849 in extensive-stage small-cell lung cancer, while managing trial pivots and competitive pressure in DLL3 therapies.
The current valuation implies that the market is not fully crediting IDEAYA Biosciences for the potential of darovasertib, the MTAP/CDKN2A/KRAS franchise, the DLL3 Topo-ADC program, and a cash balance of about US$1.24b with a stated runway into 2030.
See why 1 investors see IDEAYA Biosciences as 38% undervalued.
Result: Fair Value of $52.75 (UNDERVALUED)
Still, the bullish IDEAYA Biosciences story can break quickly if darovasertib stumbles with regulators or IDE849 struggles to stand out in a crowded DLL3 field.
Find out about the key risks to this IDEAYA Biosciences narrative.
Another View on IDEAYA Biosciences’ Valuation
The SWS DCF model points in a different direction for IDEAYA Biosciences. At a share price of $32.85, the stock trades above an estimated future cash flow value of $20.65, which frames IDEAYA as overvalued on this cash based lens. That gap raises a simple question: which story do you trust more, the pipeline narrative or the cash flow math?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out IDEAYA Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 33 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed messages on IDEAYA Biosciences so far. If the split between risks and rewards feels sharp, now is the time to scrutinize the data yourself and decide where you land with the help of 1 key reward and 1 important warning sign.
Looking for more investment ideas beyond IDEAYA Biosciences?
If IDEAYA Biosciences has you thinking harder about risk, reward, and valuation, now is the moment to broaden your watchlist with fresh, data backed opportunities.
- Spot potential mispricings early and review a curated set of 33 high quality undervalued stocks that combine solid fundamentals with prices that may sit below their estimated worth.
- Prioritise resilience and filter for 32 resilient stocks with low risk scores where financial strength and lower volatility scores help you stay focused when markets turn choppy.
- Hunt for future standouts by scanning a focused 20 high quality undiscovered gems that remain off many radars yet already show strong underlying business quality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com